<DOC>
	<DOCNO>NCT02555215</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety BG00012 subject complete Study 109MS202 ( NCT02410200 ) . Secondary objective follow : To evaluate long-term efficacy BG00012 describe long-term Multiple Sclerosis ( MS ) outcomes subject complete Study 109MS202 ( NCT02410200 ) .</brief_summary>
	<brief_title>Extension Study BG00012 Pediatric Subjects With Relapsing Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Ability parent , legal guardian , and/or subject understand purpose risk study provide sign date informed consent authorization use confidential health information accordance national local subject privacy regulation . Subjects provide assent addition parental guardian consent , appropriate , per local regulation . Subjects complete , per protocol , previous BG00012 clinical study 109MS202 ( NCT02410200 ) remain BG00012 treatment . Key Unwillingness inability comply study requirement , include presence condition ( physical , mental , social ) likely affect subject 's ability comply protocol . Any significant change medical history occur enrollment parent Study 109MS202 ( NCT02410200 ) , include laboratory test abnormality current clinically significant condition opinion Investigator would exclude subject 's participation parent study . The Investigator must rereview subject 's medical fitness participation consider factor would preclude treatment . Subjects Study 109MS202 ( NCT02410200 ) could tolerate study treatment . NOTE : Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pediatrics</keyword>
</DOC>